CDEK
← All drugs Report issue

lyb001

VaccineexperimentalCOVID-19

Clinical trial activity

8 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
4
Phase 4
0

Earliest trial started Dec 31, 2021 (NCT05125926)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06442241Phase 1Jul 31, 2024Government of China, Nucleus Network Ltd
NCT05602558Phase 2/Phase 3 (Phase 3)Dec 31, 2022Government of China
NCT05683600Phase 3Dec 29, 2022Government of China
NCT05664932Phase 3Dec 25, 2022Government of China
NCT05552573Phase 1Jul 19, 2022Government of China
NCT05928455Early Phase 1 (Phase 1)May 14, 2022Government of China, North Sichuan Medical University
NCT05137444Phase 2/Phase 3 (Phase 3)Jan 31, 2022Government of China
NCT05125926Phase 1Dec 31, 2021Government of China
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment8822021
North Sichuan Medical UniversityAcademic/Hospital1012022
Nucleus Network LtdFor profit1012024
3 organizations
Page 1 / 1